PITTSBURGH, June 4, 2014 /PRNewswire/ -- Cohera Medical, Inc.®, a leading innovator and developer of absorbable surgical adhesives and sealants, announced today the appointment of Richard W. Pascoe as a member of the Company's Board of Directors.
Mr. Pascoe is currently the Chief Executive Officer of Apricus Biosciences, Inc., a pharmaceutical company focused on the development and commercialization of novel therapeutics for men's and women's health. Mr. Pascoe joined Apricus in March of 2013 following the merger of Somaxon Pharmaceuticals with Pernix. At Somaxon Mr. Pascoe held the role of Chief Executive Officer and was responsible for the FDA approval of Somaxon's lead drug Silenor®. Prior to Somaxon, Mr. Pascoe was with ARIAD Pharmaceuticals, Inc., a specialty pharmaceutical company where he most recently acted as Senior Vice President and Chief Operating Officer.
Prior to joining ARIAD in 2005, Mr. Pascoe held a series of senior management roles at King Pharmaceuticals, Inc., a specialty pharmaceutical company, including Senior Vice President positions in both marketing and sales, as well as Vice President positions in both international sales and marketing and hospital sales. Prior to King, Mr. Pascoe was in the commercial groups at Medco Research, Inc. (which was acquired by King), COR Therapeutics, Inc., B. Braun Interventional and The BOC Group. Mr. Pascoe is also currently a member of the board of directors of KemPharm, Inc. and the Corporate Directors Forum (CDF).
Mr. Pascoe served as a Commissioned Officer with the U.S. Army 24th Infantry Division, following his graduation from the United States Military Academy at West Point where he received a B.S. degree in Leadership.
"We are excited to welcome Rich Pascoe, a seasoned healthcare executive, to our Board. His experience in both medical devices and pharmaceuticals will provide added expertise to an already strong Board," said Patrick Daly, President and CEO of Cohera Medical, Inc. "We are matriculating multiple products through the regulatory process and are preparing for our U.S. launch of TissuGlu® in the near future, so his acute awareness of growing a business like ours is paramount. We look forward to his contribution."
"Rich brings a wealth of relevant strategic experience that will prove valuable in our board deliberations as we continue to advance our lead products, TissuGlu and Sylys, to commercialization," said John C. Kern, Founder and General Partner of Kern Whelan Capital, LLC, and Manager of Kern Medical IV. "We are thrilled to have Rich join our team."
"I am delighted to welcome Rich Pascoe to the Cohera Medical Board of Directors," said Doros Platika, Chairman of Cohera Medical Inc.'s Board of Directors. "His experience with late stage biomedical and device companies includes product commercialization, IPO, and M&A that helped create shareholder value that insured liquidity and successful exits. It is further evidence that Cohera is adding to its Board of Directors the expertise necessary in a successful late stage company."
About Cohera Medical
Cohera Medical, Inc.® is a rapidly growing medical device company that is actively developing a line of surgical adhesives and sealants. Cohera Medical's products are based on a unique chemical design that is resorbable, non-toxic, easy-to-use, and forms a strong bond between tissue layers. The Company's lead product, TissuGlu® Surgical Adhesive, is indicated for the approximation of tissue layers where subcutaneous dead space exists between the tissue planes in large flap surgical procedures such as abdominoplasty. TissuGlu® is currently approved for sale in the EU and is being utilized to eliminate drains or reduce complications in patients undergoing large flap surgical procedures such as abdominoplasty (tummy tuck), mastectomy, lymph node dissection, decubitus and latissimus dorsi flap procedures. The Company's second product, Sylys® Surgical Sealant, the first synthetic sealant designed specifically to help reduce anastomotic leaks, is currently under the CE Mark approval process. TissuGlu and Sylys are the first in a pipeline of technology that includes surgical mesh adhesives, hemostatic foam, bone adhesives, and drug delivery. Outside of the EU, TissuGlu and the other Cohera Medical products are currently indicated for investigational use only and have not yet been approved for sale by the Food and Drug Administration (FDA) in the U.S. or in any other market.
For more information, visit www.coheramed.com.
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.
SOURCE Cohera Medical, Inc.